The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition

Cancer Research

Volumn 68, Issue 3, 2008, Pages 815-825

  Vigneron, Arnaud ^a,b   Gamelin, Erick ^a   Coqueret, Olivier ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA TOPOISOMERASE; EME1 ENDONUCLEASE; ENDONUCLEASE; EPIDERMAL GROWTH FACTOR RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CELL TRANSFORMATION; DNA DAMAGE; ENZYME ACTIVATION; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR UPREGULATION;

CAMPTOTHECIN; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; ENDODEOXYRIBONUCLEASES; ENZYME ACTIVATION; ENZYME INHIBITORS; HCT116 CELLS; HT29 CELLS; HUMANS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 38849086135     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5115     Document Type: Article

References (37)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-4.
2. Galizia G, Lieto E, De Vita F, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60.
3. Kim S, Prichard CN, Younes MN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 2006;12:600-7.
4. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
5. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40.
6. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
8. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
9. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J Clin Invest 1998;102:1385-92.
10. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 1999;274:17209-18.
11. Biscardi JS, Maa MC, Tice DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
12. Barré B, Vigneron A, Coqueret O. The STAT3 transcription factor is a target for the Myc and retinoblastoma proteins on the Cdc25A promoter. J Biol Chem 2005;280:15673-81.
13. Leslie K, Lang C, Devgan G, et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 2006;66:2544-52.
14. Kiuchi N, Nakajima K, Ichiba M, et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999;189:63-73.
15. Shirogane T, Fukada T, Muller JM, et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999;11:709-19.
16. Bromberg J, Wrzeszczynska M, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
17. Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001;7:517-28.
18. Catlett-Falcone R, Landowski TH, Oshiro M, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
19. Dechow TN, Pedranzini L, Leitch A, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A 2004;101:10602-7.
20. 2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005;65:8927-35.
21. Barre B, Vigneron A, Perkins N, et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11.
22. Osman F, Whitby MC. Exploring the roles of Mus81-1/Mms4 at perturbed replication forks. DNA Repair (Amst) 2007;6:1004-17.
23. Bhonde MR, Hanski ML, Notter M, et al. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 2006;25:165-75.
24. Gorgoulis VG, Pratsinis H, Zacharatos P, et al. p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions. Lab Invest 2005;85:502-11.
25. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. p53 activates ICAM-1 (CD54) expression in an NF-κB-independent manner. EMBO J 2003;22:1567-78.
26. Pommier Y, Redon C, Rao VA, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173-203.
27. Whitby MC. Junctions on the road to cancer. Nat Struct Mol Biol 2004;11:693-5.
28. Dendouga N, Gao H, Moechars D, et al. Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol 2005;25:7569-79.
29. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
30. Lee S, Schmitt CA. Chemotherapy response and resistance. Curr Opin Genet Dev 2003;13:90-6.
31. Masters JR, Koberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003;3:517-25.
32. 2-M checkpoints and promotes rereplication in human cells. Nucleic Acids Res 2006;34:880-92.
33. TaoW, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59.
34. 1 arrest in resulting tetraploid cells. Cancer Res 2001;61:7660-8.
35. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
36. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 2004;24:5172-83.
37. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 2006;25:7381-90.